6 Functionalized gold and silver nanoparticles modulate amyloid fibrillation, defibrillation and cytotoxicity of lysozyme via altering protein surface character

7 [Atrial fibrillation in the elderly].

8 Cardiotrophin-1: A new predictor of atrial fibrillation relapses after successful cardioversion.

9 Caution when comparing different defibrillation waveforms and energies. Jerry Nolan, M.D., Editor-in-Chief, Resuscitation.

10 Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry.

11 Thromboembolic, Bleeding, and Mortality Risks among Patients with Nonvalvular Atrial Fibrillation Treated with Dual Antiplatelet Therapy versus Oral Anticoagulants: A Population-Based Study.

12 Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter.

13 Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.

14 Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.

15 Initial rivaroxaban dosing in patients with atrial fibrillation.

16 Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.

17 Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.

18 Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients

19 Corrigendum to “Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis” [Arch. Gerontol. Geriatr. 81 (March–April)(2019)209–214](S0167494318302450)(10.1016/j.archger.2018.12.013)

20 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis

21 Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis

22 Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis

23 Efficacy and safety of reduced-dose non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis of randomized controlled trials

24 Economic evaluation of the use of non-Vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: A modelling analysis using the healthcare system in the Netherlands

25 Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis

26 Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis

27 Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis

28 Comment on “Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis”

29 Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

30 Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies

31 Pulmonary vein isolation in the treatment of atrial fibrillation

32 Catheter ablation in atrial fibrillation: a state-of-the-art review

33 Left atrial appendage closure devices for cardiovascular risk reduction in atrial fibrillation patients

34 Atrial fibrillation and its influence on stroke risk

35 Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking

36 Characteristics, treatment patterns, and unmet needs of Japanese patients with atrial fibrillation [Corrigendum]

37 Characteristics, treatment patterns, and unmet needs of Japanese patients with atrial fibrillation

38 Management of patients with atrial fibrillation at high risk of stroke: current treatment options

39 Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation

40 Emerging options to prevent stroke in atrial fibrillation patients

41 Clinical experience with apixaban in atrial fibrillation: implications of AVERROES

42 Dabigatran and other oral antithrombotic agents for the prevention of stroke in patients with atrial fibrillation

43 Triggers for Atrial Fibrillation: The Role of Anxiety

44 Pulmonary vein isolation in the treatment of atrial fibrillation

45 Catheter ablation in atrial fibrillation: a state-of-the-art review

46 Left atrial appendage closure devices for cardiovascular risk reduction in atrial fibrillation patients

47 Atrial fibrillation and its influence on stroke risk

48 Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking

49 Characteristics, treatment patterns, and unmet needs of Japanese patients with atrial fibrillation [Corrigendum]

50 Characteristics, treatment patterns, and unmet needs of Japanese patients with atrial fibrillation

51 Management of patients with atrial fibrillation at high risk of stroke: current treatment options

52 Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation

53 Emerging options to prevent stroke in atrial fibrillation patients

54 Clinical experience with apixaban in atrial fibrillation: implications of AVERROES

55 Dabigatran and other oral antithrombotic agents for the prevention of stroke in patients with atrial fibrillation

56 Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.

57 Ambient Air Pollution and the Risk of Atrial Fibrillation and Stroke: A Population-Based Cohort Study.

58 Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation

59 Unilateral atrial fibrillation – how common is atrial divorce?

60 Novel Method of Atrial Fibrillation Case Identification and Burden Estimation Using the MIMIC-III Electronic Health Data Set.

61 Use of insertable cardiac monitors for the detection of atrial fibrillation in patients with cryptogenic stroke in the United States is cost-effective.

62 Association between Bilateral Infarcts Pattern and Detection of Occult Atrial Fibrillation in Embolic Stroke of Undetermined Source (ESUS) Patients with Insertable Cardiac Monitor (ICM).

63 Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure.

64 Chronic inhibition of the sigma-1 receptor exacerbates atrial fibrillation susceptibility in rats by promoting atrial remodeling.

65 Television watching as sedentary behavior and atrial fibrillation: The atherosclerosis risk in communities study

66 A deep neural network for 12-lead electrocardiogram interpretation outperforms a conventional algorithm, and its physician overread, in the diagnosis of atrial fibrillation.

67 Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation.

68 Erratum: Correction in articles by Massó-van Roessel et al. "Analysis of the Association Between Electrocardiographic P-wave Characteristics and Atrial Fibrillation in the REGICOR Study", Rev Esp Cardiol. 2017;70:841-847, and by Baena-Díez et al. "Validity Assessment of Low-risk SCORE Function and SCORE Function Calibrated to the Spanish Population in the FRESCO Cohorts", Rev Esp Cardiol. 2018;71:274-282 (Revista espanola de cardiologia (English ed.) (2018) 71 4 (274-282) PII: S1885-5857(18)30159-2)

69 Prevention of ventricular fibrillation through de-networking of the Purkinje system: Proof-of-Concept Paper on the Substrate Modification of the Purkinje Network.

70 Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

71 The influence of cryoballoon manipulation on luminal esophageal temperature during ablation for atrial fibrillation.

72 Esophageal position, measured luminal temperatures, and risk of atrioesophageal fistula with atrial fibrillation ablation.

73 Atrial fibrillation incidence and impact of biventricular pacing on long-term outcome in patients with heart failure treated with cardiac resynchronization therapy

74 Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation.

75 Author response: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.

76 Reader response: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.

77 Reader response: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.

78 Editors' note: Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study.

79 Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation.

80 Post-coronary artery bypass graft atrial fibrillation event count and survival: differences by sex.

81 Changes in Electrocardiographic P Wave Parameters after Cryoballoon Ablation and Their Association with Atrial Fibrillation Recurrence.

82 Promotion Effect of Succinimide on Amyloid Fibrillation of Hen Egg-White Lysozyme.

83 Comparison of SYNTAX Score I and SYNTAX Score II for Predicting Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery.

84 Value of Syntax Score II in Prediction of New-Onset Atrial Fibrillation in Patients With NSTE-ACS Undergoing Percutaneous Coronary Intervention

85 Quantification of peripheral whole blood, cell-free plasma and exosome encapsulated mitochondrial DNA copy numbers in patients with atrial fibrillation.

86 The Correlation between Atrial Fibrillation and Prognosis and Hemorrhagic Transformation.

87 Association of erectile dysfunction with incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA).

88 Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease.

89 A new purified Lawsoniaside remodels amyloid-β fibrillation into a less toxic and non-amyloidogenic pathway.

90 Deep learning approaches for plethysmography signal quality assessment in the presence of atrial fibrillation.

91 Uptake of a primary care atrial fibrillation screening program (AF-SMART): a realist evaluation of implementation in metropolitan and rural general practice.

92 Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial

93 Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications.

94 Association of Follow-Up Care With Long-Term Death and Subsequent Hospitalization in Patients With Atrial Fibrillation Who Receive Emergency Care in the Province of Ontario.

95 High shocking and pacing impedances due to defibrillation lead calcification.

96 Initial Psychometric Testing of the Knowledge About Atrial Fibrillation and Self-Management Survey

97 Direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.

98 Novel noscapine derivatives stabilize the native state of insulin against fibrillation.

99 The impact of atrial fibrillation on accuracy of oscillometric blood pressure measurement: effect of ventricular rate.

100 Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation.

101 Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation

Keyword Connections

Journals

Research Groups

Bibliographies